- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04446962
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) (LOC-R01)
January 10, 2024 updated by: Institut Curie
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
This study is to improve the first-line induction chemotherapy, by combining either Ibrutinib, or Lenalidomide, to a conventional immuno- chemotherapy of R-MPV type (Rituximab-Methotrexate-Procarbazine-Vincristine).
This is a randomized Phase II trial, preceded by a dose escalation phase Ib.
The objective of the phase Ib is to rule out any limiting toxicity of the new treatment associations, and to determine the recommended dose of Lenalidomide and Ibrutinib to be used in the phase II.
In the phase II study, patients will receive 4 cycles of R-MPV + Lenalidomide or 4 cycles of R-MPV + Ibrutinib.
The therapeutic response will be evaluated after the 2nd and the 4th cycle.
Patients in good therapeutic response will proceed to the consolidation phase with Autologous Stem Cell Transplantation (ASCT).
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
The objective of this proposal is to test the feasibility and efficacy of two targeted induction chemotherapies obtained by adding either Lenalidomide or Ibrutinib to a standard Rituximab-High Dose (HD) Methotrexate (MTX) based induction chemotherapy regimen.
The R-MPV regimen is chosen as the backbone chemotherapy because of its wide use with robust reproducible results and a good and manageable toxicity profile
Study Type
Interventional
Enrollment (Estimated)
118
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Carole SOUSSAIN, MD
- Phone Number: +33 1 47 11 15 15
- Email: carole.soussain@curie.fr
Study Contact Backup
- Name: LYNDA CORVI
- Phone Number: +33 1 47 11 17 33
- Email: drci.promotion@curie.fr
Study Locations
-
-
-
Amiens, France
- Recruiting
- CHU Amiens
-
Contact:
- Caroline DELETTE, MD
-
Principal Investigator:
- Caroline DELETTE, MD
-
Angers, France
- Recruiting
- CHU Angers
-
Contact:
- Jérôme PAILLASSA, MD
-
Contact:
-
Principal Investigator:
- Jérôme PAILLASSA, MD
-
Bayonne, France, 64100
- Not yet recruiting
- CH Cote Basque
-
Contact:
- Sophie BERNARD, MD
-
Principal Investigator:
- Sophie BERNARD, MD
-
Besançon, France
- Recruiting
- CHU Besançon
-
Contact:
- Adrien Chauchet, MD
-
Principal Investigator:
- Adrien CHAUCHET, MD
-
Bordeaux, France
- Recruiting
- Institut Bergonie
-
Contact:
- Anna Schmitt, MD
-
Principal Investigator:
- Anna SCHMITT, MD
-
Caen, France
- Recruiting
- CHU Caen
-
Contact:
- Gandhi DAMAJ, MD
-
Principal Investigator:
- Gandhi DAMAJ, PhD
-
Clermont-Ferrand, France
- Recruiting
- CHU Clermont-Ferrand
-
Contact:
- Cécile MOLUCON-CHABROT, MD
-
Principal Investigator:
- Cécile MOLUCON-CHABROT, MD
-
Colmar, France
- Recruiting
- CH Colmar
-
Contact:
- Guido AHLE, MD
-
Principal Investigator:
- Guido AHLE Guido AHLE, MD
-
Créteil, France
- Not yet recruiting
- CHU Créteil
-
Contact:
- Louise ROULIN, MD
-
Principal Investigator:
- Louise ROULIN, MD
-
Dijon, France
- Terminated
- CHU Dijon
-
Grenoble, France
- Recruiting
- CHU Grenoble
-
Principal Investigator:
- Rémy GRESSIN, MD
-
Contact:
- Rémy Rémy GRESSIN, MD
-
Lille, France, 69000
- Recruiting
- CHRU Lille
-
Contact:
- Franck MORSCHHAUSER, PhD
-
Principal Investigator:
- Franck MORSCHHAUSER, PhD
-
Limoges, France
- Recruiting
- CHU Limoges
-
Contact:
- Julie Abraham, MD
-
Principal Investigator:
- ABRAHAM Julie, MD
-
Lyon, France
- Recruiting
- CHU Lyon
-
Contact:
- Hervé GHESQUIERES, MD
-
Principal Investigator:
- Hervé GHESQUIERES, Phd
-
Marseille, France
- Recruiting
- CHU La Timone Marseille
-
Contact:
- Olivier Chinot, MD
-
Principal Investigator:
- Olivier Chinot, MD
-
Nancy, France
- Recruiting
- CHU Nancy
-
Contact:
- Luc TAILLANDIER, PhD
-
Principal Investigator:
- Luc TAILLANDIER, PhD
-
Nantes, France
- Recruiting
- CHU Nantes
-
Principal Investigator:
- Thomas Gastinne, MD
-
Contact:
- Thomas GASTINNE, MD
-
Nice, France
- Recruiting
- Centre Lacassagne
-
Contact:
- Frédéric PEYRADE, MD
-
Principal Investigator:
- Frédéric PEYRADE, MD
-
Nîmes, France, 30029
- Not yet recruiting
- CHU Nîmes - Carémeau
-
Contact:
- Agathe WAULTIER-RASCALOU, MD
-
Principal Investigator:
- Agathe Waultier-Rascalou, MD
-
Paris, France, 75005
- Recruiting
- Institut Curie
-
Contact:
- Carole Soussain, MD
-
Principal Investigator:
- Carole Soussain, MD
-
Paris, France, 75006
- Recruiting
- Hopital Cochin
-
Contact:
- Lise WILLEMS, MD
-
Principal Investigator:
- Lise WILLEMS, MD
-
Paris, France, 75013
- Recruiting
- CHU Pitié-Salpêtrière
-
Contact:
- Caroline HOUILLIER, MD
-
Principal Investigator:
- Caroline HOUILLIER, MD
-
Poitiers, France
- Not yet recruiting
- CHU Poitiers
-
Contact:
- Vincent DELWAIL, MD
-
Principal Investigator:
- Vincent DELWAIL, MD
-
Rennes, France, 35000
- Recruiting
- CHU Rennes
-
Contact:
- Thierry LAMY De La CHAPELLE, PhD
-
Principal Investigator:
- Thierry Thierry LAMY De La CHAPELLE, PhD
-
Rouen, France, 76000
- Recruiting
- Centre Henri Becquerel
-
Contact:
- Fabrice JARDIN, PhD
-
Principal Investigator:
- Fabrice JARDIN, PhD
-
Saint Denis De La Reunion, France, 97400
- Not yet recruiting
- CHU de la Réunion
-
Contact:
- MD
-
Contact:
- Marie DE CHARETTE, MD
-
Principal Investigator:
- Marie DE CHARETTE, MD
-
Strasbourg, France, 67033
- Not yet recruiting
- Institut de Cancerologie de Strasbourg
-
Contact:
- Luc-Mathieu FORNECKER, MD
-
Principal Investigator:
- Luc-Mathieu FORNECKER, MD
-
Toulouse, France
- Recruiting
- IUCT -Oncopole
-
Contact:
- Lucie Obéric, MD
-
Principal Investigator:
- Lucie Obéric, MD
-
Tours, France
- Recruiting
- Chu Tours
-
Principal Investigator:
- Emmanuel GYAN, MD
-
Contact:
- Emmanuel GYAN, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Newly diagnosed Primary Central Nervous System Lymphoma (PCNSL).
- a) Aged between 18 and 60 (>18 and < 60) - phase IB b) Aged between 18 and 65 (≥ 18 and ≤ 65) - phase II.
- Histological confirmed diagnosis of Primary central nervous system lymphoma of Diffuse Large B-Cell Lymphomas (DLBCL) type OR patients with a measurable typical cerebral lesion on MRI with a diagnosis made by cytology and/or by flow cytometry on the vitreous or on the cerebral spinal fluid.
- Measurable lesion on MRI with gadolinium enhancement.
Adequate hematological, renal and hepatic function (Laboratory Parameters realized within 14 days before inclusion):
- Absolute neutrophil count (ANC) >1000/mm3
- Platelets > 100,000/mm3 independent of transfusion support
- Alanine aminotransferase and aspartate aminotransferase ≤ 3 x Upper Limit of Normal (ULN)
- Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin
- Estimated Glomerular Filtration Rate ≥ 60 mL/min/1.73m2.
- Able to swallow capsules.
- Karnofsky performance status: 40-100% for the phase IB and no restriction on the KPS for the phase II.
- Able to understand teratogenic risks of the Lenalidomide and Ibrutinib. Patient must be able to understand and fulfill the Lenalidomide Pregnancy Prevention Plan requirements. This plan may be accepted by the person of confidence in case of impaired cognitive status of the patient.
- Women of childbearing potential (WCBP)* and men who are sexually active must be practicing a highly effective method** of birth control. Women should avoid a pregnancy while taking treatment by Lenalidomide or Ibrutinib and for up to 1 month after ending treatment. Men must agree to not to father a child or donate sperm during treatment by Lenalidomide or Ibrutinib and up to 3 months after the last dose of study drug.
- Women of childbearing potential (WCBP)* must have a negative serum (beta-human chorionic gonadotropin [B-hCG]) or urine pregnancy test at inclusion.
- Signed informed consent, which could be signed by a person on confidence in case the neurologic status of the patient does not allow him to understand and/or to sign.
Exclusion Criteria:
- Histology other than DLBCL.
- Positive HIV serology.
- Active viral infection with Hepatitis B or C virus.
- Preexisting immunodeficiency and/or organ transplant recipient.
- Isolated Central Nervous System (CNS) relapse of systemic Non-Hodgkin's Lymphoma.
- Prior treatment for PCNSL (except corticosteroids).
- Isolated primary vitreo-retinal lymphoma.
- Major surgery, within 4 weeks prior to the first dose of study drug. Stereotactic biopsy and vitrectomy are not considered major surgery.
- History of stroke or intracranial hemorrhage (except minor post biopsy hemorrhage) within 6 months prior to inclusion.
- Requires anticoagulation with warfarin or equivalent vitamin K antagonists.
- Requires treatment with strong CYP3A4 inhibitors.
- Pregnancy or lactation.
- Clinically significant cardiovascular disease.
- Any other active malignancy, except basocellular carcinoma and non-invasive cervix cancer.
- Inclusion in another experimental anti-cancer drug therapy.
- No social security affiliation.
- Persons under legal protection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A: R-MPV with Lenalidomide
Lenalidomide in association with R-MPV as a targeted induction treatment
|
Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
Other Names:
|
Active Comparator: Arm B: R-MPV with Ibrutinib
Ibrutinib in association with R-MPV as a targeted induction treatment
|
Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Limiting Toxicity (DLT) during the first cycle of treatment for each treatment arm.
Time Frame: 1 month
|
Occurrence of a Dose Limiting Toxicity (DLT) during the first cycle of treatment for each treatment arm.
The phase Ib is a 3+3 dose escalation design
|
1 month
|
Complete Response (CR) rate including unconfirmed Complete Response (uCR) at the end of the 4 cycles of induction therapy
Time Frame: 4 months
|
The primary endpoint for the phase II part of the study is the Complete Response (CR) rate including unconfirmed CR (CR+uCR) at the end of the 4 cycles of induction therapy.
Assessment of response will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG)
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rates (CR + uCR) after 2 cycles of induction treatment
Time Frame: 2 months
|
Assessment of response will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG)
|
2 months
|
Overall response (CR + uCR + Partial Response(PR)), stable disease (SD), and primary refractory patients (PD) after 2 cycles of induction treatment
Time Frame: 2 months
|
Assessment of response will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG)
|
2 months
|
Overall response (CR + uCR + Partial Response(PR)), stable disease (SD), and primary refractory patients (PD) after 4 cycles of induction treatment
Time Frame: 4 months
|
Assessment of response will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG)
|
4 months
|
Overall Survival (OS)
Time Frame: 142 months
|
Overall Survival (OS) will be calculated from the date of randomization to the date of death, whatever the cause.
Patients alive at the date of last contact will be censored at this date.
|
142 months
|
Progression-Free Survival (PFS)
Time Frame: 142 months
|
Progression-Free Survival (PFS) will be calculated from the date of randomization to the date of progression or death (if the patient does not progress).
Patients alive without progression at the date of last contact will be censored at this date
|
142 months
|
The severity of the toxicity of treatment induction or ASCT
Time Frame: 7 months
|
Toxicity of treatment induction or ASCT will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 5.0) whenever possible and described by system organ class, preferred term
|
7 months
|
Patients who will receive ASCT
Time Frame: 7 months
|
The percentage of patients who will receive ASCT will be presented
|
7 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Steven Le GOUILL, PhD, Institut Curie
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 30, 2020
Primary Completion (Estimated)
January 15, 2024
Study Completion (Estimated)
January 15, 2031
Study Registration Dates
First Submitted
June 22, 2020
First Submitted That Met QC Criteria
June 22, 2020
First Posted (Actual)
June 25, 2020
Study Record Updates
Last Update Posted (Actual)
January 12, 2024
Last Update Submitted That Met QC Criteria
January 10, 2024
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Neoplasms by Site
- Lymphoma, B-Cell
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
Other Study ID Numbers
- IC 2019-02
- 2019-003632-23 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Sponsor will share de-identified data sets generated under the project will be disseminated in accordance with Institut Curie policies.
IPD Sharing Time Frame
Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.
IPD Sharing Access Criteria
Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Large B-Cell, Diffuse
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on Lenalidomide
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedMyelodysplastic SyndromeUnited States
-
Grupo Español de Linfomas y Transplante Autólogo...Celgene Corporation; Dynamic Science S.L.; Thermo Fisher Scientific, IncCompleted
-
Celgene CorporationICON Clinical ResearchCompletedMyelodysplastic SyndromesGermany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
-
Boston VA Research Institute, Inc.Celgene Corporation; Edward Hines Jr. VA Hospital; Michael E. DeBakey VA Medical... and other collaboratorsCompletedMultiple MyelomaUnited States
-
Swiss Group for Clinical Cancer ResearchTerminatedLymphomaSwitzerland, Norway, Sweden
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaboratorsTerminatedWaldenstrom's MacroglobulinemiaUnited States
-
University Hospital, ToulouseCelgene Corporation; Janssen-Cilag Ltd.Completed
-
CelgeneCompletedRelapsed or Refractory Chronic Lymphocytic LeukemiaUnited States, Canada, United Kingdom, France, Germany, Spain, Italy, Sweden
-
Groupe Francophone des MyelodysplasiesUnknownMyelodysplastic SyndromesFrance